Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

NCT01856283 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

87

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myeloid, Chronic-Phase

Interventions

DRUG: Nilotinib 300mg BID

Sponsor

Niguarda Hospital